Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Dabur eyes to acquire...

    Dabur eyes to acquire firms, expand in rural India with Rs 3500 crore war chest: Report

    Farhat NasimWritten by Farhat Nasim Published On 2019-12-08T09:45:52+05:30  |  Updated On 8 Dec 2019 9:45 AM IST

    “We have a ready war chest available to acquire companies,” Malhotra said, adding that Dabur has reserves of up to 35 billion rupees ($490 million). “With slow-down, some targets will become affordable which were earlier very expensive.”


    New Delhi: Dabur India Ltd., the household goods maker controlled by the billionaire Burman family, is willing to spend part of its about $500 million cash reserve to acquire companies and revive sales that grew at the slowest pace in two years.


    The company is exploring options in the health care, foods and personal care segment, Chief Executive Officer Mohit Malhotra said in an interview. Dabur has identified potential targets and is looking to buy companies in the 1 billion-to-10-billion rupee price range.


    “We have a ready war chest available to acquire companies,” Malhotra said, adding that the company has reserves of up to 35 billion rupees ($490 million). “With slow-down, some targets will become affordable which were earlier very expensive.”


    The slowest growth in six years has hit companies including Dabur, Maruti Suzuki Ltd., India’s largest carmaker, and biscuit maker Britannia Industries Ltd. as consumers in the world’s second-most populous nation cut back on purchases. Consumer confidence in India, tracked by the central bank, is at its lowest since at least 2014.


    Dabur outperformed the Sensex by 13% in the past six months.


    The company is fanning out operations to remote parts of the country to access more consumers. It is expanding its rural network to cover 55,000 villages by March next year and 60,000 by March 2021 next year from 44,000 in April, Malhotra said, adding that rural consumers account for half of the sales in the country. Revenue from Indian operations in the quarter ended Sept. 30 grew 4.1%, the slowest pace since the same quarter in 2017.


    “We are hoping to acquire the kind of entities which take us to rural India and help us bridge the gap between urban and rural image,” Malhotra said.


    Also Read: Dabur gets new CEO, Mohit Malhotra to take charge from April


    Smaller Packaging


    To keep the customers from turning to cheaper brands amid the slowing economy, Dabur started selling smaller packets of hair oils, toothpaste and fruit drinks.


    The strategy to introduce a 10-rupee packet seems to be helping the maker of Hajmola digestive candy boost sales in villages. Its rural business grew at a faster pace than urban, in contrast with rivals Hindustan UnileverNSE -0.56 % Ltd. and Marico Ltd. “Dabur has outperformed the market,” Naveen Trivedi, Analyst at HDFC Securities Ltd., wrote in a note.


    Dabur’s shares, which have risen 12% in the quarter ended Sept. 30, lost 0.74% to 462.65 rupees at 2:55 p.m. in Mumbai. Hindustan Unilever has advanced 11% in the same quarter while the benchmark Sensex fell 1.85%.


    Also Read: Dabur sues the government for denied tax sops under GST

    AcquisitionBritanniaBurmanDaburDabur IndiaHajmolaHDFCHindustan UnileverMaruti SuzukiMohit MalhotraSensextoothpaste
    Source : Bloomberg

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok